189152-83-8

Upstream product

• 189152-79-2 2,2,2-Trifluoro-1-[7-(2-mercapto-thiazol-4-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone 
• 181769-64-2 7-bromoacetyl-2-trifluoroacetyl-1,2,3,4-tetrahydroisoquinoline 
• 82771-26-4 7-acetyl-2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline 
• 189152-81-6 2,2,2-Trifluoro-1-[7-(2-tritylsulfanyl-thiazol-4-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone 

Downstream Products

• 161681-66-9 (4R,5S,6S)-6-((R)-1-Hydroxy-ethyl)-3-(4-isoquinolin-7-yl-thiazol-2-ylsulfanyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid 4-nitro-benzyl ester 

Relevant academic research and scientific papers

Synthesis and biological properties of a new series of anti-MRSA β-Lactams; 2-(thiazol-2-ylthio)carbapenems

A series of 1β-methylcarbapenems containing variously C-2 substituted thiazol-2-ylthio groups were synthesized, and their in vitro anti-MRSA activity was examined. Among them, 1β-methyl-2-(4-arylthiazol-2-ylthio) carbapenems exhibited superior anti-MRSA activity. Introduction of a cationic moiety in the C-2 side chain not only reduced the binding to HSA but also increased the stability against DHP-I, without affecting the anti-MRSA activity. It was also found that the distance between the cationic moiety and the carbapenem skeleton was related to the strength of HSA binding and the stability against DHP-I.